Krystal Biotech, Inc. (KRYS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$358.24-3.56%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Krystal Biotech grows revenue about 39% yearly, reaching $525 million in 2026. Profit and net income are rising, with operating income up $12 million since 2025. The company has a strong track record of beating earnings estimates. Its gene therapy focus targets rare diseases, a lasting demand area.
Growth may slow if new therapies face regulatory or clinical setbacks. High valuation at nearly 50x PE risks price pressure if earnings disappoint. Competition in gene therapy could limit market share gains.
The price is about 43% above our fair value near $256, reflecting analysts' expectation of 39% revenue growth. We agree growth is strong but valuation leaves limited upside without continued execution.
Breaks if: Net income falls below $51 million
Breaks if: Operating income falls below $41 million
Breaks if: Annual revenue falls below $388 million in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder in the healthcare sector. The current thesis state is intact, supported by strong recent financial performance and ongoing management priorities.
The market currently prices KRYS at a premium compared to its peers, reflecting a justified valuation. There is a slight expectations gap, indicating that the market anticipates continued performance but is cautious about potential risks.
Fundamentals are likely to remain stable, driven by management's focus on expanding the global launch of VYJUVEK and advancing their clinical pipeline. However, there are mixed signals regarding the progress of clinical studies and expense management.
The long-term thesis hinges on the ability of KRYS to maintain guidance and navigate sector trends. Key factors include the performance of sector bellwethers and the impact of economic conditions on healthcare stocks.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company beat earnings expectations with Q2 EPS of $1.79. This was higher than the expected $1.70 per share. However, revenue of $119.2 million fell short of the anticipated $122.3 million. There are no new threats to the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on increasing revenue growth through strategic initiatives.
Overall, KRYS presents a stable long-term investment opportunity, but it faces moderate risks that could impact its trajectory. Not investment advice.